Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02425904 · ClinicalTrials.gov registry record · Phase 2
Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
A Phase 2 study of Langerhans Cell Histiocytosis, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 15
- Study locations
NCT02425904 is a Phase 2 study of Langerhans Cell Histiocytosis that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 25 participants, below the 1,136-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (98% lower). The trial reports 15 study locations across 11 states.
The verdict
NCT02425904, a Phase 2 study of Langerhans Cell Histiocytosis, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 15
- Study locations
Study Summary
This research study is evaluating a drug called clofarabine as a possible treatment for Langerhans Cell Histiocytosis (LCH) and and other histiocytic disorders.
Conditions Studied
Interventions
- DRUG Clofarabine
Study Locations (15)
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Children's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
- Dana-Farber Cancer Institute - Boston
California
- Children's Hospital of Los Angeles - Los Angeles
- University of California San Francisco Medical Center - San Francisco
Arizona
- Phoenix Children's Hospital - Phoenix
Arkansas
- Arkansas Children's Hospital - Little Rock
District of Columbia
- Children's National Medical Center - Washington D.C.
New York
- Mount Sinai Medical Center - New York
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Pennsylvania
- The Children's Hospital of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-05 |
| Est. Completion | 2026-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02425904
The ClinicalTrials.gov registry entry for NCT02425904 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,136-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (98% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Langerhans Cell Histiocytosis appearing as the primary indexed condition, and to 1 intervention - of which Clofarabine is the first listed.
NCT02425904 reports 15 study locations spanning 11 distinct geographic areas - top geographies include Massachusetts, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT02425904 about?
NCT02425904 is a clinical study titled "Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders". This research study is evaluating a drug called clofarabine as a possible treatment for Langerhans Cell Histiocytosis (LCH) and and other histiocytic disorders.
What is the current status of trial NCT02425904?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2015-05. Estimated completion is 2026-07-30.
What conditions does trial NCT02425904 study?
This clinical trial studies the following conditions: Langerhans Cell Histiocytosis.
What interventions are being tested in trial NCT02425904?
The interventions under investigation include: Clofarabine (DRUG).
Who is sponsoring clinical trial NCT02425904?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02425904 being conducted?
This trial has 15 study locations across Arizona, Arkansas, California, District of Columbia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Langerhans Cell Histiocytosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
RECRUITING · Phase 2
-
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
RECRUITING · Phase 2
-
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis
COMPLETED · Phase 2
-
Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.